Abivax: Strong Buy Maintained Ahead of Q2 Obefazimod Readout and Potential Takeover Window
Abivax (ABVX) remains a compelling speculative long. Recent ECCO data reinforced obefazimod's differentiated profile, AstraZeneca holds an exclusive data-room window while Eli Lilly remains a potential re-entry candidate, and the stock trades with substantial short interest and retail liquidity. Our trade plan targets $180 with a stop at $92 and a …